Please note that we have stopped the regular imports of Gene Expression Omnibus (GEO) data into ArrayExpress. This may not be the latest version of this experiment.

E-GEOD-73624 - Gene expression profiling and TF occupancy upon treatment with the FXR agonist obeticholic acid

Status
Released on 27 January 2016, last updated on 9 February 2016
Organism
Mus musculus
Samples (8)
Protocols (3)
Description
The farnesoid X receptor (FXR) is a nuclear receptor activated by bile acids and regulates bile acid metabolism, glucose and cholesterol homeostasis. From mouse studies we know that the novel FXR agonist obeticholic acid (OCA) regulates expression of many genes in the liver, but there is currently no data on the effects of OCA on human liver gene expression. This is especially relevant since the novel FXR agonist OCA is currently tested in clinical trials for the treatment of several diseases, such as nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD) and Type 2 Diabetes. In this study we investigate the effect of OCA treatment on gene expression profiles and localization of FXR to the genome in relevant liver samples. ChIP-Seq for FXR in Liver tissue from 2 male mice treated with OCA/INT-747 (10mg/kg/day) and 2 male mice treated with vehicle (1% methyl cellulose).
Experiment type
ChIP-seq 
Contacts
Jose Miguel Ramos Pittol <j.m.ramospittol@umcutrecht.nl>, Alexandra Milona, Danielle Hollman, Jose M Ramos Pittol, Michal Mokry
Citation
Gene expression profiling in human precision cut liver slices upon treatment with the FXR agonist obeticholic acid. Ijssennagger N, Janssen AW, Milona A, Ramos Pittol JM, Hollman DA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SW, Kersten S. , PMID:26812075
MINSEQE
Exp. designProtocolsVariablesProcessedSeq. reads
Files
Links